Synthesis, crystallographic characterization, molecular docking and biological activity of isoquinoline derivatives

Hatem A. Abuelizz1*, Rashad Al-Salahi1, Jamil Al-Asri2, Jérémie Mortier2, Mohamed Marzouk3,4, Essam Ezzeldin1,5, Azza A. Ali6, Mona G. Khalil7, Gerhard Wolber2, Hazem A. Ghabbour1, Abdulrahman A. Almehizia1 and Gehad A. Abdel Jaleel8

Abstract
The main objective of this work was to synthesize novel compounds with a benzo[de][1,2,4]triazolo[5,1-α]isoquinoline scaffold by employing (dioxo-benzo[de]isoquinolin-2-yl) thiourea as a building block. Molecular docking was conducted in the COX-2 active site to predict the plausible binding mode and rationalize the structure–activity relationship of the synthesized compounds. The structures of the synthesized compounds were confirmed by HREI-MS, and NMR spectra along with X-ray diffraction were collected for products 1 and 5. Thereafter, anti-inflammatory effect of molecules 1–20 was evaluated in vivo using carrageenan-induced paw edema method, revealing significant inhibition potency in albino rats with an activity comparable to that of the standard drugs indomethacin. Compounds 8, 9, 15 and 16 showed the highest anti-inflammatory activity. However, thermal sensitivity-hot plat test, a radiological examination and motor coordination assessment were performed to test the activity against rheumatoid arthritis. The obtained results indicate promising anti-arthritic activity for compounds 9 and 15 as significant reduction of the serum level of interleukin-1β [IL-1β], cyclooxygenase-2 [COX-2] and prostaglandin E2 [PGE2] was observed in CFA rats.

Introduction
Inflammation is an important defense mechanism against infective, chemical, and physical aggressions. Deregulation of this mechanism can lead to pathological perturbations in the body, as observed for example with allergies, autoimmune diseases and organ transplantation rejection [1]. A key modulator of the inflammatory response is prostaglandin E2 (PGE2), generated at the inflammation site from arachidonic acid via the cyclooxygenase (COX) enzyme [2].

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used against inflammation, as for example in the treatment of chronic and acute inflammation [3], pain management [4], and fever [5]. However, cardiovascular problems, gastrointestinal lesions and nephrotoxicity have been observed in case of long NSAIDs treatment [6]. Therefore, the discovery of novel anti-inflammatory drugs with less side effects remains an intensive area of research in medicinal chemistry. Two isoforms of the cyclooxygenase have been characterized: COX-1 and COX-2. COX-2 levels increase after inflammatory stimuli induced by mitogens or cytokines, and can be lowered by glucocorticoids [7]. Recent discovery indicates that renal toxicity and gastrointestinal side effects observed with NSAIDs can be due to COX-1 inhibition, while selective inhibition of COX-2 shows a comparable anti-inflammatory response with less side effects [8]. As an example, naproxen is a non-selective COX inhibitor, like oxicam, it belongs to a group of NSAID displaying mixed COX inhibition, characterized by slow, reversible, and weak inhibitor binding. Contrary to other NSAIDs that inhibit COX reversibly and rapidly (mefenamic acid and ibuprofen), or irreversibly and slowly (indomethacin and diclofenac), naproxen contributes to the cardioprotective effect because of their weak inhibition of COX [9].

*Correspondence: Habuelizz@ksu.edu.sa
1 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
Full list of author information is available at the end of the article

© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The quinolone ring system is often found in synthetic compounds with various biological activities, including anti-convulsant [10], anti-malarial [11], anti-microbial [12], and anti-inflammatory [13] effects. Quinolines and their isomers isoquinolines are also found in various natural products, such as quinine (anti-malarial) and quinidine (anti-arrhythmic) [14]. Furthermore, many isoquinoline alkaloids, including cepharanthine, berberine and tetrandine, have shown anti-inflammatory effect [15]. The binding affinity and the solubility in physiological conditions can be considerably affected by the position of the nitrogen bearing a side chain on the isoquinoline skeleton [16]. Therefore, a huge effort has been spent in developing novel and effective isoquinoline derivatives. On the other hand, the triazole moiety is found in many important biologically active compounds. Synthesized molecules with a triazole moiety possess anti-tubercular [17], antimicrobial [18], anti-cancer [19] and anti-inflammatory [20] activity. Triazole-based heterocyclic derivatives have enhanced biological activity or possess new biological activities [21]. A wide range of triazole containing compounds are clinically used drugs and developed via molecular hybridization approach including anticancer, antifungal, antibacterial, antiviral, antitubercular, anti-inflammatory, antiparasitic, anti-convulsant, antihistaminic and other biological activities [21]. Therefore, triazole and isoquinoline can be promising chemical fragments for the design of novel anti-inflammatory drugs.

Considering the importance of the isoquinoline and triazole moieties in the wide range of anti-inflammatory treatments and its interesting activity profile, we conducted a molecular-hybridization design of novel anti-inflammatory compounds. Toward the development of new effective and selective anti-inflammatory agents, the [1,2,4]triazole and [5,1-α]isoquinoline were integrated to develop a novel class of inhibitor.

Materials and methods

Melting points were determined on open glass capillaries using a STUART Melting point SMP 10 apparatus and are uncorrected. NMR spectra were recorded on a Bruker AMX 500 spectrometer in DMSO-<i>d</i><sub>6</sub> and reported as δ ppm values relative to TMS at 500/700 and 125/176 MHz for <sup>1</sup>H and <sup>13</sup>C NMR, respectively; J values were recorded in Hz. HREI-MS spectra were measured on a JEOL MSStation JMS-700 system. X-ray data were collected on a Bruker APEX-II D8 Venture area diffractometer, equipped with graphite monochromatic Mo Kα radiation, λ = 0.71073 Å at 100 (2) K. Follow-up of the reactions and checking the purity of compounds was made by TLC on DC-Mikrokarten polygram SIL G/UV<sub>254</sub> from the Macherey–Nagel Firm, Duren Thickness: 0.25 mm.

Procedure for preparation of 1-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)thiourea (1)

To a solution of 1,8-naphthalic anhydride (2.2 mmol) in boiling glacial acetic acid (15 mL), thiosemicarbazide (2.8 mmol) was added and left the mixture stirring under reflux for 1 h. The obtained solid was separated and washed with water. Recrystallization by a mixture of toluene and DMF yielded the final product as colorless crystals (90%); mp 243–244 °C; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.82 (s, 1H, –NH–), 8.55 (br d, J = 8 Hz, 2H, H-3/8), 8.51 (br d, J = 8 Hz, 2H, H-5/6), 7.99 (br s, 2H, –NH₂), 7.92 (t, J = 8 Hz, 2H, H-4/7); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 181.8 (C=Σ), 162.0 (C-2/9), 134.7 (C-5/6), 131.3 (C-5a), 130.9 (C-3/8), 127.3 (C-4/7), 122.7 (C-2a/8a), 119.0 (C-2b); HRMS (EI), m/z Calcd for C<sub>13</sub>H<sub>9</sub>N<sub>3</sub>O<sub>2</sub>S (M<sup>+</sup>) 271.0983, found 271.1013.

Procedure for preparation of 10-(methylthio)-7H-benzo[de]<br>[1,2,4]triazolo[5,1-α]isoquinolin-7-one (3)

A mixture of I or 2 (1 mmol) with dimethyl-N-cyanoimidodithiocarbonate (1 mmol) in N,N-dimethyl formamide (10 mL) was refluxed in the presence of triethylamine for 4 h. Afterwards, the mixture was poured into ice/ water, the resulting solid was filtered, washed with water and dried. Analytically pure product obtained as yellow amorphous powder (67%); mp 268–269 °C; <sup>1</sup>H NMR (700 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.75 (br d, J = 7.7 Hz, 1H, H-6), 8.61 (br d, J = 8.4 Hz, 1H, H-3), 8.59 (br d, J = 8.4 Hz, 1H, H-8), 8.47 (br d, J = 7.7 Hz, 1H, H-5), 7.99 (t, J = 7.7 Hz, 1H, H-4), 7.93 (t, J = 7.7 Hz, 1H, H-7), 7.23 (s, 3H, –S–CH<sub>3</sub>); <sup>13</sup>C NMR (176 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.0 (C-9), 156.6 (>C–S–CH<sub>3</sub>), 155.9 (C-2), 137.0 (C-6), 134.3 (C-3), 133.5 (C-5), 132.3 (C-8a), 128.4 (C-8), 128.1 (C-4), 128.0 (C-7), 126.1 (C-5a), 122.9 (C-2b), 118.2 (C-2a), 14.2 (S–CH<sub>3</sub>); EI-MS, m/z (%): 267 [(M<sup>+</sup> , 100)]; HRMS (EI), m/z Calcd for C<sub>14</sub>H<sub>9</sub>N<sub>3</sub>O<sub>2</sub> (M<sup>+</sup>) 267.0466, found 267.0490.

Procedure for preparation of 10-(methylsulfonyl)-7H-benzo[de]<br>[1,2,4]triazolo[5,1-α]isoquinolin-7-one (5)

An amount of 3 (1 mmol) was dissolved in boiling glacial acetic acid (12 mL), afterward H<sub>2</sub>O<sub>2</sub> (12 mL), was added dropwise over a period of 10 min., while heating. After the addition was complete, the mixture was poured into hot water and left at room temperature, the obtained solid was collected, washed with water and dried. Recrystallization from DMF gave analytically pure colored as pale brown amorphous powder (60%); mp 218–219 °C; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.93 (br d, J = 7.5 Hz, 1H, H-6), 8.29 (br d, J = 8 Hz, 1H, H-3), 8.26 (br d, J = 8 Hz, 1H, H-8), 8.23 (br d, J = 7.5 Hz, 1H, H-5), 7.78 (t, J = 8 Hz, 1H, H-4), 7.67 (t, J = 8 Hz, 1H, H-7), 3.47 (s, 3H, –SO<sub>2</sub>–CH<sub>3</sub>); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 165.9 (C-9), 161.3 (>C–S–CH<sub>3</sub>), 160.4 (C-2), 136.0 (C-8), 128.4
(C-6), 135.9 (C-3), 131.9 (C-5), 131.7 (C-8a), 128.4 (C-8), 128.3 (C-4), 127.6 (C-7), 127.4 (C-5a), 117.3 (C-2b), 112.7 (C-2a), 42.6 (–SO₂–CH₃); HRMS (El), m/z Calcd for C₁₄H₁₃N₂O₂ (M)⁺ 299.1296, found 299.1316.

Procedure for preparation of 10-(phenoxy)-7H-benzo[de]
[1,2,4]triazolo[5,1-a]isoquinolin-7-one (4)
A mixture of 1 or 2 (1 mmol) with diphenoxy-N-cyanoimidocarbonate (1 mmol) in N,N-dimethyl formamide (10 mL) was refluxed in the presence of triethylamine for 4–5 h. Afterwards, the mixture was poured into ice/water, the obtained solid was filtered, washed with water and dried. Analytically pure product resulted as brown amorphous powder (45%); mp 281–282 °C; 1H NMR (500 MHz, DMSO-d₆): δ 8.68 (br d, J = 7.5 Hz, 1H, H-6), 8.45 (br d, J = 8 Hz, 1H, H-3), 8.31 (br d, J = 8 Hz, 1H, H-8), 8.01 (br d, J = 7.5 Hz, 1H, H-5), 7.86 (t, J = 8 Hz, 1H, H-4), 7.78 (t, J = 8 Hz, 1H, H-7), 7.48 (dt, J = 8.5, 1 Hz, 2H, H-3'/5'), 7.28 (dd, J = 8.5, 1.5 Hz, 1H, 2H, H-2'/6'), 7.16 (br t, J = 8 Hz, 1H, H-4'), 13C NMR (125 MHz, DMSO-d₆): δ 167.1 (C-OPh), 165.8 (C-9), 155.6 (C-2), 150.5 (C-1'), 136.9 (C-6), 135.1 (C-3), 133.1 (C-5), 132.7 (C-8a), 129.8 (C-3'/5'), 128.6 (C-8), 128.2 (C-4'), 127.9 (C-7), 126.3 (C-5a), 123.8 (C-4'), 122.5 (C-2b), 119.2 (C-2'/6'), 118.6 (C-2a); HRMS (El), m/z Calcd for C₁⁹H₁₁N₃O₂ (M)⁺ 313.1296, found 313.1310.

Procedure for preparation of 8-hydrazinocarbonyl-1-naphthoic acid (6)
A solution of 2 (1 mmol) in DMF (10 mL) was refluxed with Conc. HCl (15 mL) for 24 h. The mixture poured into ice/water, the obtained solid was separated, washed with water and dried. Analytically pure product resulted as yellow powder (60%); mp 225–226 °C; 1H NMR (500 MHz, DMSO-d₆): δ 14.30 (s, 1H, –COOH), 8.97 (br s, 3H, –NH–NH₂), 8.56 (br d, J = 7.5 Hz, 1H, H-2), 8.48 (br d, J = 7.5 Hz, 1H, H-4), 8.39 (br d, J = 7.5 Hz, 1H, H-5), 8.32 (br d, J = 7.5 Hz, 1H, H-7), 7.91 (t, J = 8 Hz, 1H, H-3), 7.85 (t, J = 8 Hz, 1H, H-6); 13C NMR (125 MHz, DMSO-d₆): δ 166.4 (–ONH–NH₂), 158.9 (–C=O), 158.4 (–CONH–NH₂), 135.7 (C-2), 134.9 (C-4), 132.4 (C-5), 131.9 (C-4a), 131.7 (C-8), 131.7 (C-7), 127.3 (C-6), 124.6 (C-3), 123.8 (C-8a), 117.7 (C-1); HRMS (El), m/z Calcd for C₁₂H₁₀N₂O₃ (M)⁺ 230.0691, found 230.0709.

Animals
Adult albino rats weighing 130–150 g were obtained from the animal house colony in the National Research Centre (Giza, Egypt). Animals were subjected to controlled conditions of temperature (25 ± 3 °C), humidity (50–60%) and illumination (12-h light, 12-h dark cycle, lights on at 08:00 h) and were provided with standard pellet diet and water ad libitum for 1 week before starting the experiment.

Anti-inflammatory activity
The anti-inflammatory effect was evaluated in correspondence to the carrageenan-induced paw edema method [22]. Briefly, carrageenan (1% w/v, 0.1 mL/paw) was injected into right hind paw at the plantar side. Rats were observed for abnormal behavior and physical condition after carrageenan injection. The right paw was measured once before (normal baseline) and then after carrageenan injection at 1, 2, 3, and 4 h. Twenty groups of female Sprague–Dawley rats were used (n = 6, weighing 130–150 g). According to the procedure reported in the literature, the first group represented the control carrageenan injected, the second was given indomethacin (Sigma, USA) orally, the reference anti-inflammatory drug (10 mg/kg) [23], and the remaining groups were treated with the tested compounds (25 mg/kg body-weight) orally, 1 h before carrageenan (Sigma, USA) injection. Paw volume was measure by using a water displacement plethysmometer (UGO BASILE 21025 COMERIO, ITALY). The percentage increase in paw volume was calculated using (Oedema volume of test/baseline volume) × 100. Moreover, percentage (%) inhibition was calculated using (1 – D/C) × 100, where, D-represents the percentage difference in increased paw volume after the administration of test drugs to the rats. C-represents the percentage difference of increased volume in the control groups Fig. 1.

Anti-arthritic activity
Induction of arthritis and treatment protocol
Adjuvant arthritis (AA) was induced in female Wistar rats by subcutaneous (SC) injection of 0.1 mL CFA (Sigma-Aldrich, USA) into the plantar surface of the right hind paw, which exhibits many similarities to human RA. The severity of the induced adjuvant disease was followed by measurement of the volume of the injected paw by using a water displacement plethysmometer (UGO Basile 21025, Comerio, Italy). The paw volume of the injected right paw over vehicle control is measured at every week during experiment [24]. Rats were randomly divided into four groups of six rats each: normal control, untreated arthritis group, compound 9 treated, and compound 15 treated arthritis groups. Results were expressed as the percentage increase in paw volume.

Thermal sensitivity hotplate test
Rats were placed on the hotplate at 55 °C, one at a time (Columbus Instruments, Columbus, OH). The latency period for hind limb response (e.g. shaking, jumping, or
licking) was recorded as response time. Each trial had a maximum time of 45 s. The rat was removed from the hotplate immediately after a response was observed [25].

Motor coordination assessment methods for RA
Motor coordination and balance was assessed using a rotarod apparatus (Med Associates, Italy) [26, 27]. All rats underwent a 3-day training program, by which time a steady baseline level of performance was attained. During that period, rats were trained to walk against the motion of a rotating drum at a constant speed of 12 rpm for a maximum of 2 m. In total, four training trials per day with an interval trial time of 1 h were performed. Rats falling off during a training trial were put back on the rotating drum. Following the training days, a 1-day test of three trials was performed using an accelerating speed levels (4–40 rpm) over 5 min. The apparatus was wiped with a 70% ethanol solution and dried before each trial. The mean latency to fall off the rotarod was recorded, and rats remaining on the drum for more than 300 s were removed and their time scored as 300 s.

Radiographic assessment of arthritis in rat paws
Radiographic assessment was used blindly at the end of the disease to evaluate the severity of OA radiography, using an X-ray collimator, model R-19, lamp-type 24 V, 90 W, on-load voltage 19 V (Ac max KVP 100 KVP min, inh, filt. 1 m, Japan). At the end of the experiment, 24 h after the last dose of treatment, blood samples were collected under light anaesthesia with diethyl ether by puncturing rato-orbital plexus; the blood was allowed to flow into a dry, clean centrifuge tube and left to stand 30 m before centrifugation to avoid haemolysis. Then, blood samples were centrifuged for 15 m at 2500 rpm, and the clear supernatant serum was separated and collected by Pasteur pipette into a dry, clean tube to use for determination of the serum levels of PGE2, COX2 and IL-1β [28].

Statistical analysis
Data were expressed as mean ± SEM and analysed by one-way analysis of variance (ANOVA) for multiple comparisons followed by Tukey’s post hoc comparisons. All analyses were performed by SPSS statistics package version 17.0 (SPSS, Chicago, IL, USA). P value of ≤0.05 was considered statistically significant.

Molecular modelling
All compounds were prepared using MOE (Molecular Operating Environment, 2011) and CORINA [29, 30]. Murine cyclooxygenase-2 (COX-2) enzymes co-crystallized with indomethacin (PDB entry 4COX [31, 39]) and co-crystallized with naproxen (PDB entry 3NT1 [32, 34]) were used as templates for the modeling study. Since indomethacin and naproxen have different interactions with COX-2, both inhibitors were used as references in this study [32].

The software GOLD version 5.2 [33] was used to perform docking. The crystal structure depicted under PDB entries 4COX and 3NT1 were first protonated, and water molecules as well as co-crystallized ligands were deleted before docking. In this study, default parameters were used with no constraints (binding site: within 10 Å around the co-crystallized ligand, scoring functions: GOLDScoring, genetic algorithm: 100% search efficiency). Validation of the docking protocol was performed by recovering the original conformation of the co-crystallized inhibitor inside the active site. The root mean square deviation (RMSD) between the docked pose and the crystal structure of 0.7 Å was measured for indomethacin, and 0.25 Å for naproxen (Fig. 5).

The followed strategy in this work was to generate ten docking poses for each compound using GOLD, and compare them to the one of the two co-crystallized inhibitors. This state-of-the-art approach developed in our group has been applied and validated in various recent studies [34–37]. Using the software LigandScout 3.1 [35], a 3D pharmacophore model that represents the steric interactions of the co-crystallized inhibitor inside the COX-2 pocket was created (Fig. 5) and used as a scoring function to analyze the resulting docking poses.

All generated docking poses were minimized with the MMFF94 force field inside the COX-2 pocket using LigandScout 3.1 [35]. The 3D-pharmacophore of indomethacin and the quality of the superposition of each pose with the co-crystallized ligand were used to prioritize the poses that could best explain the biological behaviors of the studied molecule. Those only were used for comparing and discussing inhibitors binding modes. LigandScout was also used for analysis, pharmacophore creation, and visualization.

Crystal structure determination for compound 5 (CCDC 1049988)
Yellow needle-shaped crystals of crystal structure determination for compound XX of C14 H9 N3 O3 S1 are, at 293 (2) K Monoclinic, space group P21/n, with a = 13.7295 (10) Å, b = 12.0853 (10) Å, c = 16.2631 (12) Å, β = 114.859 (2)°, V = 2448.4 (3) Å³ and Z = 7 formula units [d_calcd. = 1.624 Mg/m³; μ (MoKα) = 0.28 mm⁻¹]. A full hemisphere of diffracted intensities was measured using graphite monochromated MoK radiation (λ=0.71073 Å) on a Bruker SMART APEXII D8 Venture Single Crystal Diffraction System. X-rays were provided. The Bruker software package SHELXTL [36] was used to
solve the structure using “direct methods” techniques. All stages of weighted full-matrix least-squares refinement were conducted using $F^2$ data with the SHELXTL software package.

The final structural model incorporated anisotropic thermal parameters for all non hydrogen atoms and isotropic thermal parameters for all hydrogen atoms. The remaining hydrogen atoms were included in the structural model as fixed atoms (using idealized sp$^3$- or sp$^3$-hybridized geometry and C–H bond lengths of 0.95–0.98 Å) “riding” on their respective carbon atoms. The isotropic thermal parameters for these hydrogen atoms were fixed at a value 1.2 (non-methyl) or 1.5 (methyl) times the equivalent isotropic thermal parameter of the carbon atom to which they are covalently bonded. A total of 369 parameters were refined using no restraints and 2 data. Final agreement factors at convergence are: $R_1$ (unweighted, based on $F$) = 0.096 for 4307 independent “observed” reflections having $2\theta$ (MoKα)< 50.0° and $I > 2(I)$; $wR_2$(weighted, based on $F^2$) = 0.264 for all 2979 independent reflections having $2\theta$ (MoKα)< 50.0°.

**Results**

**Chemistry**

As dioxo-benzo[de]isoquinolin-2-ylthiourea (1) was required as key starting material (see Scheme 1), it was previously prepared by the reaction of 1,8-naphthalic anhydride (A) with thiosemicarbazide. This compound was then characterized by X-ray crystallography (Figs. 2, 3) [37]. The symmetric structure of the 2-amino-1H-benzo[de]isoquinolin-1,3-dione moiety in 1 shows similar NMR splitting patterns and δ-values (δ H and δ C) to A, including three pairs of two equivalent aromatic protons (H-3/8, H-5/6 and H-4/7) and their corresponding $^{13}$C-signals. Presence of the thio-urea moiety was supported by the –NH and –NH$_2$ singlets at δ$_H$ 9.82 and 7.99, respectively alongside C=S carbon at 181.8 in $^{1}$H and $^{13}$C NMR spectra. Finally, HREI-MS confirmed the identity of 1 through a molecular ion peak (M)$^+$ at $m/z$ 271.1013 calculated for 271.0983 and a MF of $C_{13}H_{9}N_{3}O_{2}S$. Reaction of 1 with hydrazine hydrate in presence of NaOH produced product 2 in good yields (78%). Structure of 2 was confirmed by $^{13}$C-NMR analysis, which showed
the disappearance of C=S at 181.80 ppm. Based on the high reactivity of 1 towards hydrazine, it was anticipated that 1 would react with N-cyanoimido(dithio)carbonates in a similar manner in presence of Et₃N to give novel benzo[de][1,2,4]triazolo[5,1-a]isoquinolines 3 and 4. Further oxidation of methylthio in 3 using H₂O₂ yielded in the novel benzo[de][1,2,4]triazolo[5,1-a]isoquinoline 5. Similarly, treatment of 2 or 6 with N-cyanoimido(dithio) carbonates with basic medium, resulted in compounds 3 and 4, respectively (Scheme 1).

Ring-closure of products 3–5 was reflected into the deformation of the symmetrical structures of the 2-aminooisoquinoline moiety, which appeared in the ¹H NMR spectra as four broad doublets (H-3, 5, 6 and 8) and two triplicates (H-4, 7) signals. Also, ring-closure of a fused triazole ring was confirmed from the characteristic δ values of C-2 (∼156–160 ppm), carbonyl-carbon (C-9) at δ 166 ppm and the methylthio-, methylsulfonyl- and phenoxy-bearing carbon signals at 156.6, 161.3 and 167.1, respectively. ¹H NMR of 3 and 5 showed a characteristic singlet of methylthio and methylsulfonyl at δ 2.73 and 3.74 together with their carbons at 14.2 and 42.6 ppm, respectively, to prove the insertion of such functional groups. The phenoxy group in the structure of 4 was concluded through its characteristic resonances at 7.48 (dt, J = 8.5), 7.28 (dd, J = 8.5) and 7.16 (br t, J = 8.5), attributable for H-3′/5′, H-2′/6′, and H-4′, and their C-signals at δ 129.8, 119.2, and 123.8, respectively. The success of the previous reactions was finally proven by the unambiguous confirmation of the 3D-structure of methylsulfonyl product 5 by X-ray crystallography (Figs. 2, 3). The open structure 6 was obtained by heating compound 2 with concentrated HCl in DMF for 24 h under reflux (Scheme 1). This structure was confirmed by the two singlets at δ 14.30 and 8.97 ppm, interpretable for –COOH and –NH–NH₂ protons, together with the corresponding carbonyl ¹³C-resonances at δ 166.4 and 158.9, for –COOH and –CONHNH₂, respectively. Compounds 7–20 were synthesized from 2-amino-1H-benzo[de]
isoquinolin-1,3-dione (2) (Table 1) and reported in our previous work [38].

**Anti-inflammatory activity**

In-vivo anti-inflammatory effects of the synthesized benzo[de]isoquinolines 1–20 were then evaluated using standard carrageenan-induced paw edema in rats, indomethacin as reference drug. Paw swelling is good index for evaluating and assessing the degree of inflammation and the therapeutic and curative effects of bioactive compounds. The response of target compounds 1–20 ranged from weak to moderate activity, however, some of compounds exhibited promising effects in a direct correlation with their structural variation. In comparison to the control and reference drugs, all investigated compounds show significant reduction of paw size throughout a 4 h time period (Additional file 1: Table S1; Fig. 1).

**Anti-arthritic activity**

In chronic inflammation, CFA-induced arthritic model is considered the best known experimental model of rheumatoid arthritis (RA) and a model of chronic polyarthritis with features that resemble RA. Basis on the promising anti-inflammatory activity results of compounds 9 and 15, we extended our research to evaluate their anti-arthritic effects in doses of 50 mg/kg administered orally. For monitoring the progression of arthritis in a CFA-induced albino rat model, a number of assessment methods as thermal sensitivity hotplate, motor coordination and radiographic were applied. The changes in the body weight of the CFA-induced arthritis in rat with compounds was measured (Fig. 4a). Measurement of paws was performed by using a plethysmometer (Fig. 4b). The sensitivity and reaction to pain stimulus was indicated by hotplate (Fig. 4c). The serum level of Interleukin-1β (IL-1β, cyclooxygenase-2 (COX2) and prostaglandin E2 (PGE2) of the CFA treated rat were measured and compared to the control group (Table 2). Soft tissue with normal bone density of the rat’s hind paws was examined by X-ray (Additional file 1: Figure S1A).

**Table 1  Synthesized compounds 1–20**

| No | R          | No | R          | No | R          | No | R          |
|----|------------|----|------------|----|------------|----|------------|
| 7  |            | 11 |            | 15 |            | 19 |            |
| 8  |            | 12 |            | 16 |            | 20 |            |
| 9  |            | 13 |            | 17 |            |     |            |
| 10 |            | 14 |            | 18 |            |     |            |
With the aim to predict the most plausible binding mode of the identified inhibitors in this work and to rationalize their structure–activity relationship (SAR), molecular docking was performed in the COX-2 active site. To investigate the inhibition of these synthesized compounds, ten docking conformations were generated, carefully analyzed and prioritized using a 3D-pharmacophore representation of the binding modes of the reference inhibitors, indomethacin and naproxen. Since the sequence of murine COX-2 active site is 87% identical to the one in human, PDB entry 4COX of murine COX-2 co-crystallized with indomethacin, and PDB entry 3NT1 co-crystallized with naproxen were selected for this computer-aided study [39]. The docking program GOLD 5.2 [33] was used to reproduce the binding mode of the co-crystallized indomethacin in the ligand–protein complex 4COX [39] and the co-crystallized naproxen inside the complex 3NT1 [32]. The root mean square deviation (RMSD) between the heavy atoms of the original co-crystallized ligand, and the docked conformation ligand was calculated in GOLD 5.2. Validation of docking experiments for the PDB codes 4COX and 3NT1 for COX-2 enzyme are depicted in Additional file 1: Figure S2. The co-crystal of indomethacin in the COX-2 active site (PDB entry 4COX) and naproxen inside the COX-2 active site (PDB entry 3NT1) were analyzed (Fig. 5 a, b).

Docking results were evaluated by MolDock score function and hydrogen bond and hydrophobic interactions between tested compounds and the target receptor were used to compare between the tested compounds and the reference compounds (Table 3).

**Molecular modelling**

Table 2 Effect of test compounds 50 mg/kg on serum IL-1β, COX2 and PGE2 of rat CFA

|                  | IL-1β (pg/mL) | COX2 (ng/mL) | PGE2 (pg/mL) |
|------------------|---------------|--------------|--------------|
| Control (vehicle) | 26.8 ± 1.4    | 15.9 ± 0.4   | 17.3 ± 0.9   |
| CFA              | 93 ± 2.2      | 463 ± 1.5    | 659 ± 2.3    |
| Compound 9       | 374 ± 1.1     | 169 ± 0.2    | 226 ± 0.7    |
| Compound 15      | 419 ± 0.9     | 208 ± 0.5    | 254 ± 0.3    |

Data represent the mean ± SEM (n = 6 for each group)

a Significance versus control (P ≤ 0.05)
b Significance versus CFA group (P ≤ 0.05)

**Fig. 4 a** Changes in body weight of CFA-induced RA in rat with compounds 9 and 15. **b** Effect of test compounds (50 mg/kg) on CFA-induced arthritis in rats with compounds 9 and 15. **c** Effect on hotplate time response with compounds 9 and 15. **d** Effect on spontaneous motor activity in CFA rats with compounds 9 and 15. Data represent the mean ± SEM (n = 6 for each group); *significance versus control (P ≤ 0.05); #significance versus CFA group (P ≤ 0.05)
in the COX-2 active site. Three kinds of interactions can be identified for indomethacin inside COX-2 active site: hydrophobic contacts between aromatic rings of indomethacin and hydrophobic residues Phe381, Leu384, Met522, Tyr385, Trp387, Leu531, Ala527 and Val523 in the active site, a salt bridge formed between Arg120 and the carboxylate group of the inhibitor, and hydrogen bonds between the inhibitor and Tyr355, Arg120, and Ser530. The original conformation of indomethacin in the crystal structure 4COX was used as a reference for investigating and prioritizing the generated docking poses. The resulting conformations of the studied compounds were analyzed and the most plausible poses were selected based on their ability to create similar interactions as the one of the reference inhibitor.

Table 3  MolDock scores of tested compounds

| Ligand       | MolDock score | Ligand | MolDock score |
|--------------|---------------|--------|---------------|
| 1            | −99.3452      | 11     | −114.071      |
| 2            | −98.9549      | 12     | −109.498      |
| 3            | −107.022      | 13     | −111.854      |
| 4            | −121.189      | 14     | −103.154      |
| 5            | −68.9738      | 15     | −128.385      |
| 6            | −92.9481      | 16     | −94.8682      |
| 7            | −108.334      | 17     | −98.9912      |
| 8            | −110.781      | 18     | −128.489      |
| 9            | −106.802      | 19     | −104.212      |
| 10           | −120.592      | 20     | −71.3571      |
| Indomethacin | −151.314      |        |               |
Docking of compound 15 reveals an ability to partially accommodate the same region as the reference inhibitor inside the pocket (Fig. 6). Compound 15 shows binding through hydrophobic contacts formed between its fused aromatic rings and Val523 and Val349, as observed for indomethacin. Additional hydrophobic contacts can be formed between the fused aromatic rings and Ala527, Leu531, Leu352, and Phe518. One hydrogen bond can be formed between the carbonyl oxygen of 15 and Tyr355. Superposition of 15 with indomethacin shows how both ligands can occupy the same region in the pocket, which can explain why 15 is the most potent inhibitor in this series (Fig. 6).

Docking with naproxen as reference inhibitor

Naproxen is another reference inhibitor that is stabilized in the active site of COX-2 with a different binding mode compared to indomethacin. It is important to investigate the ability of our compounds to interact with COX-2 using a binding mode more similar to the one of naproxen as the one of indomethacin. Therefore, the generated binding conformations of our inhibitor series was aligned to a 3D-pharmacophore model extracted from the COX-2-naproxen co-crystal (PDB entry 3NT1) [32]. The ability of these molecules to fulfill similar interactions as the one identified in this crystal structure was analyzed using LigandScout.

The plausible binding mode of 9, the most potent inhibitor in this series, shows interesting interactions with the binding site of COX-2. Besides the stabilization of ligands inside the pocket with hydrophobic contacts, hydrogen bonds can be formed between the methoxy of compound 9 (up to 72%) and Arg120, and a carbonyl of 9 with Ser530 (Fig. 7). This interaction may serve to anchor the compound within the active site similar to naproxen and enforce the binding orientation.

Discussion

The results revealed that many of the tested compounds caused significant decrease in paw edema after 1, 2, 3, 4 h from drug administration. The edema inhibition percentages measurements show that after 1 h compounds 2, 3, 12, 14 and 18 were inactive. The same result was observed after 4 h with compound 20. Compounds 4, 10, 11, 13, and 19 showed low activity (0.63, 9.60, 11.75, 10.12 and 10.36% of inhibition, respectively) 1 h after drug administration, while 12 and 18 showed 14.89 and 17.60% of inhibition after 2 h. 1 h after drug administration, compounds 5–7, 9, 16, 17 and 20 were found to possess a good biological response (from 20.61 to 31.45%) compared to indomethacin (18.98%), and compound 15 emerged as the most potent (66.13%), 3.5 more than reference indomethacin (Additional file 1: Table S1). With respect to the effect of indomethacin after 2 h, a similar tendency were observed for compounds 8 and 15; 1, 5–8, 11, 13, 16, 17 and 20 showed a comparable good activity; a moderate effect was observed by 2–4, 10, 14 and 19, however, compound 9 showed a stronger effect (72.72%) than indomethacin (61.22%). Similarly, after 3 h, compounds 6, 8, 9 and 14–17 showed good activity (56.55–71.09%); and moderate inhibition was observed for compounds 1–5, 7, 10–13, 19 and 20 (31.72–48.09%), while indomethacin inhibited 80.15% of the induced edema. 4 h after drug administration, compounds 1, 6, 8,
and 13–18 exhibited remarkable and significant activity (51.67–67.20%) compared to indomethacin (85.70%); a moderate effect was observed for compounds 3–5, 7 and 11 (32.81–46.66%), and compounds 2, 10, 12 and 19 showed the lowest potency (Fig. 1).

Transformation of 1 into 2–4 attenuated the anti-inflammatory effect. However, subsequently transformation of 2 and 3 into 6 and 5 respectively, was offered advantageous influencing in the terms of activity. Opening the bulky-sized structure 2 into 6 is crucial for inducing the anti-inflammatory effects. Various effects were recorded upon chemical transformation of 2 into 7–20, particularly compounds 8, 9 and 14 that appeared to be the most active products among aldehyde derivatives 7–14. This could be attributed to the presence of hydroxyl group on benzyl ring in the structure of 8, and methoxy group in 9 which they could be displayed an essential role in activity. However, the presence of a hetero atom in 14 does seem to offer remarkable advantage for activity. This indicates that increasing the number of hetero atoms that can act as hydrogen bond donor could be responsible for the improvement of anti-inflammatory activity. Incorporation of a crucial structural feature of cyclohexyl isothiocyanate in 2 to afford 15 increased the anti-inflammatory activity. Furthermore, an improvement in the activity was observed by insertion of succinic anhydride function in the structure of 2 to give 16.

In regards to chronic inflammation, compound 9 and 15 have demonstrated a significant effect on the CFA-induced arthritic model. When compounds 9 and 15 were administered daily for 3 weeks (starting from day 7 of the CFA induction); non-significant change in body weight was noticed, however a significantly reduction (52%) on the body weight of the CFA-induced RA group was observed in comparison to the control group (Fig. 4a). As illustrated in Fig. 4b, an adjuvant injection resulted in an acute inflammatory phase of swelling in the injected paws for 3 days and an autoimmune phase of swelling in both injected and non-injected paws after 10 days. Compounds 9 and 15 markedly reduced the volumes of injected paws in comparison to the CFA (RA) group.

The sensitivity and reaction to pain stimulus was indicated by hotplate, to which the response of the CFA rats was slower than the control group. Treatment of the CFA rats with compounds 9 and 15 normalized the response compared to the control group (Fig. 4c), significantly altered the total number of movements ($P \leq 0.05$) in the locomotor activity at the end of the experiment (Fig. 4d), and reduced the serum level of Interleukin-1β (IL-1β), cyclooxygenase-2 (COX2) and prostaglandin E2 (PGE2) compared to the control group (Table 2).

Examination of the rats hind paws by X-ray showed normal soft tissue with normal bone density (Additional file 1: Figure S1A). Aggravated swelling with bone erosion in the articular facet and joint space that was practically devastated was observed after 28 days from CFA induction (Additional file 1: Figure S1B). Treatment with compounds 9 and 15 showed increasing swelling of soft paw tissue with a diminution in bone density (Additional file 1: Figure S1C) and some minimal soft tissue swelling (Additional file 1: Figure S1D) respectively.

Kinetic, mutagenesis, structure–activity relationship analysis and x-ray crystallography studies of naproxen and indomethacin elucidated the molecular determinants for COX inhibition [32]. Because a detailed comparison of the binding mode of these two drugs could unveil the responsible features for selectivity, analysis of
the enzyme-inhibitor interaction for indomethacin and naproxen co-crystallized with COX-2 was conducted using a pharmacophore approach with software Ligand Scout [35]. Compounds 1–20 have MolDock scores range from −68.9 to −128.4. Compounds 18 and 15 which have highest MolDock score in this experiment 128.4 and 128.3, respectively. Compound 15 which has the best percentage of edema inhibition in this study give also best MolDock score (Table 3). The co-crystal of indomethacin in the COX-2 active site (PDB entry 4COX) shows three critical interactions: (i) hydrophobic contacts between aromatic rings of indomethacin and hydrophobic residues Phe381, Leu384, Met522, Tyr385, Trp387, Leu531, Leu352, Ala527 and Val523 in the active site (ii) a salt bridge formed between Arg120 and the carboxylate group of the inhibitor, and (iii) hydrogen bonds between the inhibitor and Tyr355, Arg120, and Ser530 (Fig. 5a). Analysis of naproxen inside the COX-2 active site (PDB entry 3NT1) indicates a binding mode similar from the one of indomethacin. The key interactions with Arg120 and Tyr355 with the carboxylate group of the ligand interactions are conserved, and most hydrophobic contacts observed in the main pocket are accommodating the lipophilic moieties of the inhibitor. The only difference between the two inhibitors is the chlorobenzoyl group of indomethacin that reaches another region of the active site (Tyr385, Leu384, Phe381) that naproxen cannot reach because of its smaller size (Fig. 5b).

The investigation of docking conformations for the most potent inhibitors in this series indicates the important role of hydrophobic contacts to stabilize ligands inside the pocket. However, the lack of interaction with the critical Tyr385 with most of these series implies their moderate/weak potencies against COX-2. Interestingly, Compound 15 shows fast inhibitory potency (66%) from the first hour and remains relatively stable even after 4 h (58%). Thus, it is worth to investigate this series using a reference such as naproxen that has different binding mode compared to indomethacin. The binding conformation of compounds 15 and 9 forming hydrogen bonds with Tyr355 in similar manner to naproxen confirms the importance of Tyr355 and confirms the findings highlighted with indomethacin. Also, the unique formation of hydrogen bond between Arg120 and naproxen can be observed with compounds 9 and 15. This result suggests that the most potent inhibitor in this series, compound 15, has a binding mode that is highly correlated with the conformation of naproxen inside COX-2 active site. Moreover, compound 9 can interact through Leu352, Val349, Ser530, Trp387, Tyr385 and its carbonyl group with Tyr355 by hydrogen bonding. These interactions can explain that compound 9 is higher potency than compound 15 (up to 66%), which lacks these interactions.

By using a combined approach of biological activity and molecular modeling, we were able to probe the importance of 9 and 15-COX-2 interactions and elucidate key interactions and compare it with indomethacin and naproxen. The combination of mutagenesis and structural studies will clearly define the contribution of protein and inhibitor atoms to affinity with compound 9 and 15, which will be applied in the future.

**Conclusion**

The present investigation explored the significance of the molecular-hybridization development of novel compounds with strong activity against the inflammation-induced-by-carrageenan model. Compounds 8, 9, 15 and 16 were the most potent compounds of the series, which can be explained by a similar binding mode to references indomethacin and naproxen. Moreover, the results presented here support the notion that compound 9 and 15 are active against rheumatoid arthritis and significantly reduce the serum level of Interleukin-1β [IL-1β], cyclooxygenase-2 [COX2] and prostaglandin E2 [PGE2] in the CFA rats. The investigation of the inhibitor in the COX-2 binding site by molecular modeling confirms the importance of the hydrogen bonds formation with Tyr355 and Arg120 and its role in the potency of the newly synthesized inhibitors. Furthermore, the hydrophobic contacts formed by compounds 9 and 15 with Tyr385 suggest binding modes that are highly correlated with the conformation of naproxen and indomethacin inside COX-2 active site. These compounds offer a base for further investigation of a novel anti-inflammatory and anti-arthritic agents.

**Additional file**

**Additional file 1: Table S1.** Reduction of rats paw edema induced by carrageenan after administration of tested compounds. [Figure S1](#). Radiological characteristics of hind paws of arthritic rats. [Figure S2](#).

**Abbreviations**

ORTEP: Oak Ridge Thermal-Ellipsoid Plot Program, [IL-1β]: interleukin-1; COX: cyclooxygenase; PGE2: prostaglandin E2.

**Authors’ contributions**

RA, MM, HAA, conceived and designed the chemistry experiments; EE, AZA, MGK, GJ performed the biological experiments; JA, JM, GW, AAA performed Molecular modeling; HAG performed X-ray; RA, MM, HAA, JA interpreted the results; HAA, EE, RA, MM analyzed the data; HAA, RA wrote and revised the paper; all co-authors revised the final manuscript. All authors read and approved the final manuscript.
Author details
1 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia. 2 Department of Pharmaceutical & Medicinal Chemistry, Institute of Pharmacy, Freie Universität Berlin, Königin-Luise Str. 2-4, 14195 Berlin, Germany. 3 Department of Chemistry, College of Science and Humanities, Prince Sattam bin Abdulaziz University, 83, Alkhair, Saudi Arabia. 4 Chemistry of Natural Products Group, Center of Excellence for Advanced Sciences, National Research Centre, Dokki, Cairo 12622, Egypt. 5 Drug Bioavailability Lab., College of Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia. 6 Department of Pharmacology & Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt. 7 Department of Pharmacology & Toxicology, Faculty of Pharmacy, Dokki, Cairo 12622, Egypt. 8 Department of Pharmacology, National Research Centre, El-Bohout St, Dokki, Cairo 12622, Egypt.

Acknowledgements
The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding this work through the research Project No. RS-16-02-22.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval
All animal care and procedures were in accordance with the European Communities Council Directive (24-11-1986) and were approved by Ethics Committee of National Research Centre, Egypt.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 1 June 2017 Accepted: 18 August 2017
Published online: 16 October 2017

References
1. Shuttleworth SJ, Bailey SG, Townsend PA (2010) Histone deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets 11:1430–1438
2. Serhan CN, Levy B (2003) Success of prostaglandin E2 in structure-function: a challenge for structure-based therapeutics. Proc Natl Acad Sci USA 100:8606–8611
3. Sng BL, Schug SA (2009) The role of opioids in managing chronic non-cancer pain. Ann Acad Med Singap 38:960–966
4. Zahiradnik HP, Hanjalic-Beck A, Groth K (2010) Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review. Contraception 81:185–196
5. Eccles R (2006) Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu. J Clin Pharm Ther 31:309–319
6. Martinez-Fleites C, Proctor M, Roberts S, Bolam DN, Gilbert HJ, Davies GJ (2006) Insights into the synthesis of lipopolysaccharide and antibiotics through the structures of two retaining glycosyltransferases from family GT4. Chem Biol 13:1143–1152
7. O’Banion MK, Winn VD, Young DA (1992) cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 89:4888–4892
8. Chattopadhyay M, Kodela R, Duvalsaint PL, Kashfi K (2016) Gastrointestinal safety, chemotherapeutic potential, and classic pharmacological profile of NOSH-naproxen (AVT-219) a dual NO- and H2S-releasing hybrid. Pharmacol Res Perspect 4
9. Gerse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC (1999) Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J 339:607–614
10. Guan LP, Jin QH, Wang SF, Li FN, Quan ZS (2008) Synthesis and anticonvulsant activity of S-phenyl-[1,2,4]-triazolo[4,3-a]quinolines. Arch Pharm Chem 341:774–779
11. N'Da DD, Breytenbach JC, Smith PJ, Lategan C (2010) Synthesis, cytotoxicity and antimalarial activity of ferrocenyl amides of 4-aminoquinolines. Arzneimittelforschung 60:627–635
12. Al-Salahi R, Abuelizz HA, Dib RE, Marzouk M (2016) Antimicrobial activity of new 2-thioxo-benzo[g]quinazolin-4(3H)-one derivatives. Med Chem 9:9
13. Mortier J, Frederick R, Ganef C, Remouchamps C, Talaga P et al (2010) Pyrazolo[4,3-c]isoquinolines as potential inhibitors of NF-κB activation. Biochem Pharmacol 79:1462–1472
14. Griffith KS, Lewis LS, Malis S, Parise ME (2007) Treatment of malaria in the United States: a systematic review. JAMA 299:2264–2277
15. Yasukawa K, Takido M, Ikekawa T, Shimada F, Takeuchi M, Nakagawa S (1991) Relative inhibitory activity of berberine-type alkaloids against 12-O-tetradecanoylphorbol-13-acetate-induced inflammation in mice. Chem Pharm Bull 39:1462–1463
16. Werbel LM, Angelo M, Fry DW, Worth DF (1986) Basically substituted ellipticine analogues as potential antitumor agents. J Med Chem 29:1321–1322
17. Kucukozguel I, Kucukozguel SG, Rollas S, Kiraz M (2001) Some 3-thioxo/alkylthio-1,2,4-triazoles with a substituted thiourea moiety as possible antimycobacterials. Bioorg Med Chem Lett 11:1703–1707
18. Al-Salahi R, Abuelizz HA, Wadi M, El Dib RA, Alothani MA, Marzouk M (2016) Antimicrobial activity of synthesized 2-methylthiobenzog[1,2,4]triazolo[1,5-a]quinazoline derivatives. Med Chem 12:760–766
19. Hou YP, Sun J, Pang ZH, Lu PC, Li DD et al (2011) Synthesis and antitumor activity of 1,2,4-triazoles having 1,4-benzodioxan fragment as a novel class of potent methionine aminopeptidase type II inhibitors. Bioorg Med Chem 19:5948–5954
20. Kumar H, Javed SA, Khan SA, Amir M (2008) 1,3,4-Oxadiazole/thiadiazole and 1,2,4-triazole derivatives of biphenylyl-4-xyloxy acetic acid: synthesis and preliminary evaluation of biological properties. Eur J Med Chem 43:2688–2698
21. Zhou CH, Wang Y (2012) Recent researches in triazole compounds as medicinal drugs. Curr Med Chem 19:239–280
22. Winter CA, Risley EA, Nuss GW (1962) Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc Soc Exp Biol Med 111:544–547
23. Garbacki N, Titts M, Angenot L, Damas J (2004) Inhibitory effects of proanthocyanidins from Ribes nigrum leaves on carrageenin acute inflammatory reactions induced in rats. BMC Pharmacol 4:25
24. Newbould BB (1965) Chemotherapy of arthritis induced in rats by mycobacterial adjuvant. Br J Pharmacol Chemother 21:127–136
25. Fox RL, Herrmann ML, Frangou CG, Wahl GM, Morris RE et al (1999) Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 93:198–208
26. Vonsy JL, Ghandehari J, Dickenson AH (2009) Differential analgesic effects in naive mice using an accelerating rotarod. J Pharm Pharmacol 61:544–547
27. Andersen ML, Santos EH, Maria de Lourdes V, da Silva AA, Tufik S (2004) Evaluation of acute and chronic treatments with Harpagophytum procumbens on Freund’s adjuvant-induced arthritis in rats. J Ethnopharmacol 91:325–330
28. Fox RH, Hidding L, Frangou CG, Wahl GM, Morris RE et al (1999) Mechanism of action of leflunomide in rheumatoid arthritis. Clin Immunol 93:198–208
29. Vonsy JL, Ghandehari J, Dickenson AH (2009) Differential analgesic effects of morphine and gabapentin on behavioural measures of pain and disability in a model of osteoarthritis pain in rats. Eur J Pain 13:786–793
30. Andersen ML, Santos EH, Maria de Lourdes V, da Silva AA, Tufik S (2004) Evaluation of acute and chronic treatments with Harpagophytum procumbens on Freund’s adjuvant-induced arthritis in rats. J Ethnopharmacol 91:325–330
31. Chen S, Roberts DJ (1968) The quantitative measurement of motor inco-ordination in naive mice using an accelerating rotarod. J Pharm Pharmacol 20:302–304
32. Sadowski J, Gasteiger J, Klebe G (1994) Comparison of automatic three-dimensional model builders using 639 X-ray structures. J Chem Inf Comput Sci 34:1000–1008
33. Kim SC, Singh AN, Rauhuel FM (1988) Analysis of the galactosyltransferase reaction by positional isotope exchange and secondary deuterium isotope effects. Arch Biochem Biophys 267:54–59
34. Hansen SF, Bettler E, Rinnan A, Engelsen SB, Breton C (2010) Exploring genomes for glycosyltransferases. Mol Biosyst 6:1773–1781
35. Duggan KC, Walters MJ, Murre J, Harp JM, Kiefel JR et al (2010) Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen. J Biol Chem 285:34950–34959
36. Jones G, Willett P, Glenn RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727–748
34. Al-Asri J, Fazekas E, Lehoczki G, Perdih A, Gorick C et al (2015) From carbohydrates to drug-like fragments: rational development of novel alpha-amylase inhibitors. Bioorg Med Chem 23:6725–6732
35. Wolber G, Langer T (2005) LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 45:160–169
36. Hubschle CB, Sheldrick GM, Dittrich B (2011) ShelXle: a Qt graphical user interface for SHELXL. J Appl Crystallogr 44:1281–1284
37. Al-Salahi R, Al-Omar M, Marzouk M, Ng SW (2012) N-[2,4-Dioxo-3-aza-tricyclo-[7.3.1.0(5,13)]trideca-1(13),5,7,9,11-pentaen-3-yl]thio-urea. Acta Crystallogr Sect E Struct Rep Online 68:1811
38. Al-Salahi R, Marzouk M (2014) Synthesis of novel 2-amino-benzo[de]isoquinolin-1,3-dione derivatives. Asian J Chem 26
39. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA et al (1996) Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384:644–648